Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Mar / Breaking Bad Genetics
Genetics and epigenetics Omics Molecular Pathology

Breaking Bad Genetics

Regulatory RNA-binding protein hnRNP H1 may play a role in the genetics of methamphetamine sensitivity and other substance addictions

By Michael Schubert 03/29/2016 1 min read

Share

Some of us may have heard people say, “Addiction runs in my family.” And it’s common knowledge that substance abuse is driven by genetic, as well as environmental factors. It’s only recently, though, that a group of researchers from Boston University School of Medicine have identified a gene that demonstrates a causal relationship to addiction – specifically, to methamphetamine sensitivity (1). “Both genes and environment can exert independent and interactive influences on an individual’s risk for developing an addiction throughout life,” explains corresponding author Camron Bryant. “Gene discovery is one important piece of the puzzle in understanding the neurobiological adaptations that confer risk versus resistance to the addictions throughout development and into adulthood.” Bryant and his colleagues employed an unbiased, discovery-based approach called quantitative trait locus (QTL) mapping in mice; they sought broad chromosomal regions causally associated with variations in sensitivity to the methamphetamine locomotor stimulant response – a behavior is associated with activation of the dopamine reward circuitry in the brain. “We honed in on a particular region of a chromosome by using a ‘fine mapping’ approach to identify the smallest possible region necessary for differential drug responding. The region we identified contained only two protein-coding genes, which we mutated to identify the causal factor.” The gene Bryant and his colleagues ultimately discovered is called heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1), which codes for an RNA-binding protein that regulates hundreds of genes in the brain.

“An obvious next step is to determine whether or not this novel factor is genetically associated with methamphetamine addiction in humans,” says Bryant. “That would strengthen the impact of our findings and could have implications for prescribing psychostimulant drugs like Adderall or Ritalin, which have similar molecular mechanisms of action to methamphetamine.” At the moment, the researchers are developing the tools to identify the brain region-specific RNA targets of hnRNP H1 and assessing its contribution to behavioral traits more closely aligned with addiction, including conditioned drug reward and self-administration of drugs of abuse. They are also extending their findings to other disease models known to be associated with dysfunction of RNA binding proteins. Gene expression analysis indicates a role in dopaminergic neuron development – meaning that hnRNP H1 may play a role not only in addiction, but in neurological disorders like ADHD, schizophrenia, and Parkinson’s disease.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. N Yazdani et al., “Hnrnph1 is a quantitative trait gene for methamphetamine sensitivity”, PLoS Genet, 11, e1005713 (2015). PMID: 26658939.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.